A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Part of paid clinical trials in Lake Forest, California.

Sponsor
Alnylam Pharmaceuticals
Study ID
NCT07553442
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ALN-AGT01 RVR — DRUG
    ALN-AGT01 RVR will be administered subcutaneously (SC)
  • Placebo — DRUG
    Placebo will be administered SC
  • Zilebesiran — DRUG
    Zilebesiran will be administered SC

Study Details

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Key Dates

Start date
Apr 27, 2026
Status verified
May 2026
Primary completion
Apr 1, 2028
Completion
Oct 1, 2028

Study Design

Enrollment
93 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ALN-AGT1 RVR
    Participants will be administered a single dose of zilebesiran followed by a single dose of ALN-AGT01 RVR.
  • Placebo Comparator: Placebo
    Participants will be administered a single dose of zilebesiran followed by a single dose of placebo.

Primary Outcome Measure

Part A: Percentage recovery from baseline in serum AGT [ Time Frame: Up to Day 4 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Clinical Trial SiteLake ForestCalifornia92630-
Clinical Trial SiteTampaFlorida33602-
Clinical Trial SiteSavannahGeorgia31401-

Find similar trials in Lake Forest, CA

By condition
Hypertension (high blood pressure)
By specialty
CardiologyHeart disease
By research site
Clinical Trial Site· Lake Forest, CAClinical Trial Site· Tampa, FLClinical Trial Site· Savannah, GA

Related Studies